



Biologics

- October 2023 -

Biologics Funding - October 2023 By Amount Raised (1 of 4)

Total financings for category exceeded \$2.5B (50% of total), across 30 deals.

Date	Company	Investment Cluster	About	Investment (\$M)	Round	Investors
10-04	Madrigal Pharmaceuticals	Philadelphia	Madrigal Pharmaceuticals is a biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases.	\$500.00	Post IPO Equity	Public Offering
10-02	Amicus Therapeutics	New Jersey	Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.	\$400.00	Post IPO Debt	Blackstone
10-24	Aiolos Bio	San Francisco	Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.	\$245.00	Series A	co-led by Forbion, Atlas Venture, Bain Capital Life Sciences, and Sofinnova Investments with additional investment from RA Capital Management.
10-30	Viridian Therapeutics	Boston	Biopharma company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Leveraging their expertise in antibody discovery and engineering.	\$185.00	Post IPO Equity	
10-23	Harpoon Therapeutics	San Francisco	Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.	\$150.00	P.I.P.E	Soleus Capital, Commodore Capital, New Leaf Venture Partners, RA Capital Management, Ally Bridge Group, Lion Point Capital, K2 HealthVentures, Surveyor Capital, Cormorant Asset Management, Invus, and a large mutual fund.
10-11	Agomab Therapeutics	Europe	AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.	\$100.00	Series C	Fidelity Management & Research Company, EQT Life Sciences, Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors

Biologics Funding - October 2023 By Amount Raised (2 of 4)

Date	Company	Investment Cluster	About	Investment (\$M)	Round	Investors
10-10	SAB Biotherapeutics	South Dakota	SAB Biotherapeutics is a clinical-stage biopharmaceutical development company focusing on human immunoglobulins to treat and prevent immune and autoimmune disorders	\$100.00	Post IPO Equity	
10-16	Scholar Rock	Boston	Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.	\$97.80	Post IPO Equity	
10-26	Triveni Bio	Boston	Triveni Bio focuses on the identification of novel disease by combining human genetics and precision medicine.	\$92.00	Series A	co-led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.
10-23	Aligos Therapeutics	San Francisco	liver and viral disease	\$92.00	Post IPO Equity	Armistice Capital, Deep Track Capital, EcoR1 Capital and Roche Venture Fund, among others.
10-16	Atom Bioscience	China	Atom Bioscience is a clinical-stage biotechnology company.	\$83.00	Series D	Kaitai Capital, Fortune Capital, Huajin Investment, Unifortune and NNFE Investmen
10-20	ManaT Bio	Washington D.C. / Baltimore	ManaT Bio is a biotechnology company that offers genetic and innunological therapeutic services.	\$72.10	Venture	Catalio and Third Rock
10-05	ALX Oncology	San Francisco	ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.	\$63.20	Private Equity Round	
10-01	Adlai Nortye	New Jersey	Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.	\$57.50	IPO	
10-09	LimmaTech Biologic	Europe	LimmaTech Biologic AG is a clinical stage biopharmaceutical company. GlycoVaxyn spinout's tech platform and pipeline designed to tackle bacterial infections.	\$37.00	Series A	Adjuvant Capital, AXA IM Alts and the Novo Holdings REPAIR Impact Fund

Biologics Funding - October 2023 By Amount Raised (3 of 4)

Date	Company	Investment Cluster	About	Investment (\$M)	Round	Investors
10-04	Shorla Oncology	Europe	Shorla Pharma is an Irish specialty pharmaceutical company focusing on womens oncology	\$35.00	Series B	Kurma Partners' Growth Opportunities Fund, Seroba Life Sciences Enterprise Ireland, and Irish-, U.S.- and Canadian-based family offices
10-31	Imagine Pharma	Pittsburgh	Drug discovery and development company that offers a platform to provide therapeutic and regenerative medicine.	\$32.50	Series A	IP Investors LLC
10-02	Amicus Therapeutics	New Jersey	Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.	\$30.00	Post IPO Equity	Blackstone
10-18	Actym Therapeutics	San Francisco	Actym's proprietary platform, S. Typhimurium-Attenuated Cancer Therapy (STACT), represents a new approach to achieving a comprehensive immunological re-activation of the Tumor Microenvironment (TME) for the treatment solid tumors.	\$25.50	Series A2	co-led by existing investors Boehringer Ingelheim Venture Fund and Illumina Ventures, with GKCC LLC as a new investor joining the round with Actym's other current shareholders, Panacea Ventures and JLo Ventures.
10-31	Theratechnologies	Canada	Theratechnologies is a bio-pharmaceutical company, engages in the discovery of therapeutic products for commercialisation.	\$25.00	Post IPO Equity	Public Offering
10-12	Edesa Biotech	Canada	Edesa develops treatments for dermatological and anorectal diseases.	\$16.70	Grant	Gov't of Canada
10-17	Lumen Bioscience	Seattle	Lumen Bio discovers, develops, and manufactures biologic drugs and vaccine candidates for various diseases.	\$16.20	Grant	US Dept of Defence
10-12	Synerkine Pharma	Europe	Synerkine Pharma is a developer of fusion proteins for the treatment of chronic pain.	\$12.80	Series A	Flerie Invest, Utrecht Health Seed Fund, Thuja Capital, InnovationQuarter

Biologics Funding - October 2023 By Amount Raised (4 of 4)

Date	Company	Investment Cluster	About	Investment (\$M)	Round	Investors
10-25	Flashpoint Therapeutics	Chicago	Flashpoint Therapeutics introduces a new way to building cancer immunotherapies.	\$10.00	Seed	led by Beta Lab, a leading deep tech venture capital firm headquartered in Riyadh, Saudi Arabia, with participation from leading private equity investor Russell Carson's CS Venture Opportunities Fund.
10-02	Mogrify	Europe - UK	Mogrify® will transform the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.	\$10.00	Series A	Parwalk Advisors, Astellas Venture Management, Trend Investment Group, Ahren Innovation Capital
10-05	Laminar Pharma	Europe	Laminar Pharma is a biopharmaceutical company performing discovery, rational design and initial clinical development of new MLT-based drugs.	\$9.80	Venture	Dentol Capital
10-12	Edesa Biotech	Canada	Edesa develops treatments for dermatological and anorectal diseases.	\$7.20	Post IPO Debt	
10-31	OKYO Pharma	Europe - UK	biopharmaceutical company developing innovative therapies for the treatment of inflammatory DED and NCP	\$5.84	Post IPO Equity	Institutional Investor
10-25	Sonnet BioTherapeutics	New Jersey	Sonnet BioTherapeutics is a biotechnology company for innovating biologic drugs of the single or bispecific mechanism of action.	\$4.55	Private Equity Round	
10-25	Oxurion	Europe	Oxurion is a biotech drug development company focused on developing therapies for retinal disorders, now focusing on diabetic eye diseases.	\$1.50	Post IPO Debt	Atlas Special Opportunities